Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2014

View Archived Issues

Acceleron begins phase I trial of new muscle drug

NIH awards funding to Rare Diseases Clinical Research Network

Boston Strategics enters agreement with Molecular Response

Domainex and Auspherix collaborate to develop antibiotics to treat resistant bacterial infections

ZERO Cancer Research Fund supports prostate cancer early detection work at UCSF

Pentamer Pharmaceuticals seeks crowdfunding to support Ebola virus vaccine development

Heidelberg Pharma extends ADC research collaboration with Roche

Selecta, JDRF and Sanofi to develop a synthetic vaccine particle immunotherapy for type 1 diabetes

New data provided on anti-inflammatory cystic fibrosis candidate CTX-4430

In vivo and in vitro data for novel antisense oligonucleotide for the treatment of CF

Bayer Schering Pharma patents new Wnt signaling inhibitors for cancer

Scientists at Global Blood Therapeutics divulge novel prodrugs for sickle cell disease

Novel IDO inhibitors disclosed by Bristol-Myers Squibb

Sanofi Pasteur and Immune Design collaborate on a herpes simplex virus vaccine

AbbVie Board withdraws recommendation of proposed business combination with Shire

Novel FABP inhibitors synthesized by Roche

Cellular Biomedicine launches preclinical research study for COPD

Phase III safety and immunogenicity results for DTaP-IPV in children 4-6 years of age

Phase III results from ESTEEM 1 and 2 trials evaluating apremilast in patients with psoriasis

University of Utah develops use of peptide mimics as a drug target for Ebola

Allegro initiates phase II study of Luminate for DME

U.S. orphan drug designation for radiotracer OPS-202

Duvelisib misses primary endpoint in phase IIa asthma study

Pharmacyclics and Roche to test ibrutinib and obinutuzumab combination in lymphoma and leukemia

Identification of a novel nuclear-encoded mitochondria susceptibility loci for schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...